Literature DB >> 2932139

A report of two long-surviving cases of pulmonary lymphangioleiomyomatosis and the response to progesterone therapy.

E H Sawicka, A J Morris.   

Abstract

Two cases of pulmonary lymphangioleiomyomatosis, with survival between 12 and 28 years are described. Both were treated with medroxyprogesterone acetate with a slight initial improvement in both lung function and exercise tolerance, and no further deterioration during the period of follow-up of 10-20 months. The results are discussed and other reports of hormonal treatment of this rare condition are reviewed.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2932139     DOI： 10.1016/0007-0971(85)90077-4

Source DB:  PubMed          Journal:  Br J Dis Chest        ISSN： 0007-0971


  9 in total

Review 1.  Rare diseases. 1. Lymphangioleiomyomatosis: clinical features, management and basic mechanisms.

Authors:  S Johnson
Journal:  Thorax       Date:  1999-03       Impact factor: 9.139

Review 2.  Minireview: Lymphangioleiomyomatosis (LAM): The "Other" Steroid-Sensitive Cancer.

Authors:  Hen Prizant; Stephen R Hammes
Journal:  Endocrinology       Date:  2016-07-13       Impact factor: 4.736

3.  Lymphangiomyomatosis: a respiratory illness with an endocrinologic therapy.

Authors:  H O Sieker; K S McCarty
Journal:  Trans Am Clin Climatol Assoc       Date:  1988

4.  Pulmonary tuberous sclerosis treated with tamoxifen and progesterone.

Authors:  C J Westermann; A C Oostveen; S S Wagenaar; C Hilvering; S E Overbeek; D Verheijen-Breemhaar; B Corrin
Journal:  Thorax       Date:  1986-11       Impact factor: 9.139

5.  Uterine-specific loss of Tsc2 leads to myometrial tumors in both the uterus and lungs.

Authors:  Hen Prizant; Aritro Sen; Allison Light; Sung-Nam Cho; Francesco J DeMayo; John P Lydon; Stephen R Hammes
Journal:  Mol Endocrinol       Date:  2013-07-02

6.  Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management.

Authors:  Francis X McCormack; Nishant Gupta; Geraldine R Finlay; Lisa R Young; Angelo M Taveira-DaSilva; Connie G Glasgow; Wendy K Steagall; Simon R Johnson; Steven A Sahn; Jay H Ryu; Charlie Strange; Kuniaki Seyama; Eugene J Sullivan; Robert M Kotloff; Gregory P Downey; Jeffrey T Chapman; MeiLan K Han; Jeanine M D'Armiento; Yoshikazu Inoue; Elizabeth P Henske; John J Bissler; Thomas V Colby; Brent W Kinder; Kathryn A Wikenheiser-Brokamp; Kevin K Brown; Jean F Cordier; Cristopher Meyer; Vincent Cottin; Jan L Brozek; Karen Smith; Kevin C Wilson; Joel Moss
Journal:  Am J Respir Crit Care Med       Date:  2016-09-15       Impact factor: 21.405

7.  Effect of a gonadotrophin-releasing hormone analogue on lung function in lymphangioleiomyomatosis.

Authors:  Sergio Harari; Roberto Cassandro; Iacopo Chiodini; Jacopo Chiodini; Angelo M Taveira-DaSilva; Joel Moss
Journal:  Chest       Date:  2007-12-10       Impact factor: 9.410

Review 8.  Lymphangioleiomyomatosis and tuberous sclerosis complex.

Authors:  Dimitrios Chorianopoulos; Grigoris Stratakos
Journal:  Lung       Date:  2008-04-12       Impact factor: 2.584

9.  Relation of pulmonary lymphangio-leiomyomatosis to use of the oral contraceptive pill and fertility in the UK: a national case control study.

Authors:  I Wahedna; S Cooper; J Williams; I C Paterson; J R Britton; A E Tattersfield
Journal:  Thorax       Date:  1994-09       Impact factor: 9.139
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.